Cerecin previously Accera Revenue and Competitors

Denver, CO USA



Total Funding



Estimated Revenue & Valuation

  • Cerecin previously Accera's estimated annual revenue is currently $6.7M per year.(i)
  • Cerecin previously Accera's estimated revenue per employee is $175,395
  • Cerecin previously Accera's total funding is $70.1M.

Employee Data

  • Cerecin previously Accera has 38 Employees.(i)
  • Cerecin previously Accera grew their employee count by -3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Cerecin, previously Accera, Inc., is a global healthcare company focused on developing brain health solutions and therapeutics for patients around the world. Cerecin is led by an expert executive management team with globally recognized specialists in central nervous system diseases and supported by two partners, Nestle Group and Wilmar Ventures Pte. Ltd. Cerecin's lead compound, tricaprilin, is intended to address the metabolic deficit that is known to be characteristic of Alzheimer's disease by providing the brain with an alternative energy substrate. Cerecin is currently preparing this newly reformulated compound for global pivotal studies. Bringing together the deep industry expertise of its leadership team and the extensive market access capabilities of its strategic investors, Cerecin is growing its global presence to build a brighter future for Alzheimer's patients.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Cerecin previously Accera's People

VP Finance & North American OperationsReveal Email/Phone
Chief Medical OfficerReveal Email/Phone
President & CEOReveal Email/Phone
Senior Manager, CMC FormulationReveal Email/Phone
ScientistReveal Email/Phone
Director Clinical Quality AssuranceReveal Email/Phone

Cerecin previously Accera News

2021-10-19 - Cerecin Raises $40M in Series II and IIA Financing

Cerecin, Inc., a Denver, CO- Melbourne, Australia- and Singapore-based clinical-stage biotechnology company pioneering innovative neurotherapeutics, raised USD $40m in Series A financing. A Series II investment was initially made by long-term investor, Nestlé. In follow up to this round, Series ...

2018-10-05 - Cerecin Raises US$50M in Funding

Cerecin, previously Accera, Inc., a Singapore-based brain health-focused pharmaceutical company, raised US$50M in the first close of an investment round. This funding was composed of both equity investment and non-dilutive grants. The round was led by new investor Wilmar Ventures Pte. Ltd., a ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding